According to the Credit Suisse report, "Gleevec/Glivec is used much more frequently in the first line setting in the EU than the US (74% vs. 46%)." Using those percentages, until the EPIC results are in, Iclusig only has the possibility of being used in second-line 26% of the time in the EU (other than T315I).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.